Stockscreener 앱 받기
33.88
1.69%
0.3987
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan - Stock Titan
BEAMBeam Therapeutics Inc Latest SEC Filings - Finviz
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock - Moomoo
Form 144 BEAM THERAPEUTICS INC. For: 29 June By Investing.com - Investing.com South Africa
FMR LLC sells $10.04 million in Beam Therapeutics shares By Investing.com - Investing.com Australia
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise - Stock Titan
Form 4 Beam Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
FMR LLC sells $10.04 million in Beam Therapeutics shares - Investing.com
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale - Stock Titan
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 2000 Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 3000E Value Benchmark - marketscreener.com
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM) - TradingView
Top Beam Therapeutics (BEAM) Competitors 2026 - MarketBeat
BEAM Forecast — Price Target — Prediction for 2027 - TradingView
Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM) - TradingView
Price to sales forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBIT forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBITDA forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
The Technical Signals Behind (BEAM) That Institutions Follow - Stock Traders Daily
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Beam Therapeutics stock soars 21% in three months: Here's why - MSN
Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading - Stock Titan
Beam Therapeutics stock hits 52-week high at 36.66 USD By Investing.com - Investing.com Australia
Beam Therapeutics stock hits 52-week high at 36.66 USD - Investing.com
Clinical: Beam Advances Base Editing For PKU - CRISPR Medicine News
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - The Globe and Mail
Beam Therapeutics (BEAM) Receives FDA Approval for BEAM-304 IND Application - GuruFocus
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial - Stock Titan
Beam Therapeutics gets FDA clearance for BEAM-304 - grafa.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial - Investing.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial By Investing.com - Investing.com South Africa
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beam Therapeutics Inc (BEAM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beam Therapeutics Inc (BEAM) Institutional Confidence - TradingKey
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why - The Globe and Mail
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts? - Insider Monkey
1.42%
자본화:
|
볼륨(24시간):